MEVP (Middle East Venture Partners)

Middle East Venture Partners is a Dubai-headquartered MENA venture firm that has been one of the more active early and growth-stage tech investors in the region for over a decade. The fund writes Seed, Series A, and Series B checks broadly in the $1M to $5M range, with selective participation in larger growth rounds, and its sector mandate explicitly includes digital health, health IT, and AI-enabled platforms. The fund’s MENA reach spans UAE, Saudi Arabia, Egypt, Lebanon, Jordan, and Bahrain, with deal teams that have lived through multiple regional cycles. The right founder is a MENA operator building a B2B or B2C platform with a credible regional wedge, comfortable with a fund that runs concentrated positions and stays involved at the board level. Healthcare relevance includes telemedicine, clinic and hospital operations software, AI clinical decision support layered on regional data, pharmacy and supply chain platforms, and consumer health products with realistic unit economics in Gulf and Levant markets. Founders pursuing biotech, MedTech with multi-year clearance pathways, or capital-intensive brick-and-mortar care should look at Gulf-specific PE. Geographic advantage is meaningful: MEVP’s relationships with Gulf family offices, sovereign-adjacent capital, and regional corporates can shape go-to-market and follow-on rounds in ways that pure financial diligence cannot replicate. The fund has historically syndicated with global Tier-1 investors at Series B and beyond, which de-risks the path to scale. Best entry is a warm intro from a portfolio founder or a regional co-investor such as Wamda, Algebra, or Raed; cold inbound is read but conversion is lower. Lead the pitch with real revenue, credible Gulf customer relationships, and a sober view on cross-border expansion mechanics across MENA, since each market has its own healthcare regulator, payer system, and language requirements. AI healthcare founders should describe Arabic-language NLP performance, data residency posture under Saudi PDPL and UAE rules, and clinical model validation. Caveats: at $1M to $5M checks, MEVP is often a co-lead rather than a sole anchor in larger rounds, so founders should confirm the lead-versus-co-lead expectation early. Ask the fund about reserves, prorata behavior, and which Series B leads it has brought in. Confirm the fund’s vintage and remaining deployment. Reference checks with current portfolio CEOs on responsiveness, operating support, and behavior in down rounds are particularly important for regional GPs that have seen multiple capital cycles. Used appropriately, MEVP is one of the more credible regional partners for MENA healthcare and AI founders building toward Gulf scale.